1460773636-9105d802-a6f4-4168-883b-7f34ab028a31

1. A method comprising:
a) sparging a liquid with an electrolysis cell that lacks an ion exchange membrane;
b) electrochemically activating the sparged liquid to produce a sparged anolyte electrochemically activated (EA) liquid and a sparged catholyte EA liquid with a functional generator comprising an anode chamber and a cathode chamber, which are separated by an ion exchange membrane, wherein the sparged liquid feeds the anode chamber and the cathode chamber; and
c) performing the sparging step a) and the electrochemical activating step b) along a flow path through the electrolysis cell and the functional generator that lacks a liquid feedback path from an output of either the electrolysis cell or the functional generator.
2. The method of claim 1 and further comprising:
d) dispensing the sparged anolyte EA liquid and the sparged catholyte EA liquid separately.
3. The method of claim 1 and further comprising:
d) onboard an apparatus, combining all of the sparged anolyte EA liquid with all of the sparged catholyte EA liquid to produce a combined sparged anolyte and catholyte EA liquid; and
e) dispensing substantially all of the combined sparged anolyte and catholyte EA liquid from the apparatus to a surface to be cleaned upon electrochemical activation in step b) without an intermediate step of storing.
4. The method of claim 3, wherein the step of combining in step d) is performed without valving.
5. The method of claim 1 and further comprising:
d) performing steps a), b), and c) onboard a mobile surface cleaning apparatus.
6. The method of claim 1, wherein the sparging of step a) further comprises sparging at least by a mechanical process.
7. The method of claim 1, wherein the liquid that is electrochemically activated in step b) consists essentially of tap water.
8. The method of claim 1, wherein the liquid that is electrochemically activated in step b) consists of tap water.
9. The method of claim 1, wherein the liquid of step a) comprises water and an electrolyte concentration that is greater than zero and does not exceed 1.0 moles per liter.
10. A method comprising:
a) electrochemically activating a liquid to produce an anolyte electrochemically activated (EA) liquid and a catholyte EA liquid with a functional generator comprising an anode chamber and a cathode chamber, which are separated by an ion exchange membrane;
b) sparging at least one of the anolyte EA liquid, the catholyte EA liquid or both of the anolyte EA liquid and the catholyte EA liquid with an electrolysis cell that lacks an ion exchange membrane; and
c) performing the electrochemically activating step a) and the sparging step b) without feeding any of the anolyte EA liquid, catholyte EA liquid or the liquid sparged by the electrolysis cell back to an input f the functional generator.
11. The method of claim 10 and further comprising:
d) separately dispensing at least one of the sparged anolyte EA liquid and the sparged catholyte EA liquid.
12. The method of claim 10 and further comprising at least one of the following steps:
d) combining all of the anolyte EA liquid with all of the catholyte EA liquid to produce a combined anolyte and catholyte EA liquid; or
e) combining all of the sparged anolyte EA liquid with all of the sparged catholyte EA liquid to produce a combined sparged anolyte and catholyte EA liquid.
13. The method of claim 12, wherein the step of combining in step d) is performed without valving.
14. The method of claim 10 and further comprising:
d) performing steps a), b) and c) onboard a mobile surface cleaning apparatus; and
e) dispensing substantially all sparged anolyte and catholyte EA liquid from the apparatus to a surface to be cleaned upon electrochemical activation in step a) and sparging is step b) without an intermediate step of storing.
15. The method of claim 10, wherein the sparging of step b) further comprises sparging at least by a mechanical process.
16. The method of claim 10, wherein the liquid of step a) consists essentially of tap water.
17. The method of claim 10, wherein the liquid of step a) consists of tap water.
18. The method of claim 10, wherein the liquid of step a) comprises water and an electrolyte concentration that is greater than zero and does not exceed 1.0 moles per liter.
19. A method comprising:
a) sparging a liquid with an electrolysis cell that lacks an ion exchange membrane to produce a sparged liquid;
b) feeding the sparged liquid into an anode chamber and a cathode chamber of a functional generator, the anode and cathode chambers being separated by an ion exchange membrane;
c) electrochemically activating the sparged liquid to produce a sparged anolyte liquid and a sparged catholyte liquid with the functional generator;
d) onboard an apparatus, combining all of the sparged anolyte liquid with all of the sparged catholyte liquid to produce a combined sparged anolyte and catholyte liquid; and
e) dispensing substantially all of the combined sparged anolyte and catholyte liquid as a working liquid from the apparatus to a surface to be cleaned upon electrochemical activation in step c).
20. The method of claim 19, and further comprising:
f) performing steps a) through d) along a flow path through the electrolysis cell and the functional generator that lacks a liquid feedback path to either the electrolysis cell or the functional generator.
21. The method of claim 19, wherein the step of combining in step d) is performed without valving.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for inducing or facilitating analgesia in a subject in need thereof, wherein a therapeutically effective amount of a peptide of 5 to 50 amino acids length comprising the amino acid sequence NPFPTX1X2KRX3X4 (SEQ ID NO: 2) wherein X1, X2, X3, and X4 may be the same or different and each is an amino acid residue, is administered via a transbuccal route.
2. The method according to claim 1, wherein the peptide comprises the acid sequence NPFPTX1X2KRX3X4 (SEQ ID NO: 2) wherein X1 is absent or is W, X2 is absent or is R, X3 is P or K and X4 is absent or is G or H.
3. The method according to claim 1, wherein the peptide comprises the amino acid sequence NPFPTWRKRPG (SEQ ID NO: 3), NPFPTRKRP (SEQ ID NO: 4), NPFPTWRKRP (SEQ ID NO: 5), NPFPTWKRKH (SEQ ID NO: 6) or a derivative, homologue, analogue or mimetic of SEQ ID NOs: 3-6.
4. The method according to claim 1, wherein the peptide is administered via a sublingual route.
5. The method according to claim 1, wherein the peptide is comprised in liquid solution, orally disintegrating tablet, bioadhesive tablet, microsphere or nanosphere of any shape, film, lollipop, chewing-gum, mouthwash, toothpaste, buccal drop or spray.
6. A method for preventing or treating pain in a subject in need thereof, wherein a therapeutically effective amount of a peptide comprising the amino acid sequence NPFPTX1X2KRX3X4 (SEQ ID NO: 2) wherein X1, X2, X3, and X4 may be the same or different and each is an amino acid residue, is administered via a transbuccal route.
7. The method according to claim 6, wherein the peptide comprises the acid sequence NPFPTX1X2KRX3X4 (SEQ ID NO: 2) wherein X1 is absent or is W, X2 is absent or is R, X3 is P or K and X4 is absent or is G or H.
8. The method according to claim 6, wherein the peptide comprises the amino acid sequence NPFPTWRKRPG (SEQ ID NO: 3), NPFPTRKRP (SEQ ID NO: 4), NPFPTWRKRP (SEQ ID NO: 5), NPFPTWKRKH (SEQ ID NO: 6) or a derivative, homologue, analogue or mimetic of SEQ ID NOs: 3-6.
9. The method according to claim 6, wherein the peptide is administered via a sublingual route.
10. The method according to claim 6, wherein the peptide is comprised in a liquid solution, orally disintegrating tablet, bioadhesive tablet, microsphere or nanosphere of any shape, film, lollipop, chewing-gum, mouthwash, toothpaste, buccal drop or spray.
11. The method according to claim 6, wherein the pain is an inflammatory pain or an acute or chronic pain.
12. The method according to claim 6, wherein the pain is a symptom of a condition associated with nitric oxide synthase.
13. A pharmaceutical composition comprising a peptide of 5 to 50 amino acids which comprises the amino acid sequence NPFPTX1X2KRX3X4 (SEQ ID NO: 2) wherein X1, X2, X3, and X4 may be the same or different and each is an amino acid residue, wherein said composition is in a form suitable for a transbuccal administration.
14. The pharmaceutical composition according to claim 13, wherein the peptide comprises the acid sequence NPFPTX1X2KRX3X4 (SEQ ID NO: 2) wherein X1 is absent or is W, X2 is absent or is R, X3 is P or K and X4 is absent or is G or H.
15. The pharmaceutical composition according to claim 13, wherein the peptide comprises the amino acid sequence NPFPTWRKRPG (SEQ ID NO: 3), NPFPTRKRP (SEQ ID NO: 4), NPFPTWRKRP (SEQ ID NO: 5), NPFPTWKRKH (SEQ ID NO: 6) or a derivative, homologue, analogue or mimetic of SEQ ID NOs: 3-6.
16. The pharmaceutical composition according to claim 13, wherein the composition is a liquid solution, orally disintegrating tablet, bioadhesive tablet, microsphere or nanosphere of any shape, film, lollipop, chewing-gum, mouthwash, toothpaste, buccal drop or spray.
17. The pharmaceutical composition according to claim 13, wherein the composition is in a spray.
18. The pharmaceutical composition according to claim 13, wherein the composition is in an orally disintegrating tablet.